[go: up one dir, main page]

FR2846009B1 - SCREENING OF MOLECULES WITH ANTI-PRION ACTIVITY: KITS, METHODS AND CRIBLE MOLECULES - Google Patents

SCREENING OF MOLECULES WITH ANTI-PRION ACTIVITY: KITS, METHODS AND CRIBLE MOLECULES

Info

Publication number
FR2846009B1
FR2846009B1 FR0308289A FR0308289A FR2846009B1 FR 2846009 B1 FR2846009 B1 FR 2846009B1 FR 0308289 A FR0308289 A FR 0308289A FR 0308289 A FR0308289 A FR 0308289A FR 2846009 B1 FR2846009 B1 FR 2846009B1
Authority
FR
France
Prior art keywords
molecules
screening
crible
kits
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0308289A
Other languages
French (fr)
Other versions
FR2846009A1 (en
Inventor
Marc Blondel
Stephane Bach
Christophe Cullin
Nicolas Talarek
Jean Michel Vierfond
Yvette Renoult Mettey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite Victor Segalen Bordeaux 2
Universite de Poitiers
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite Victor Segalen Bordeaux 2
Universite de Poitiers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0213022A external-priority patent/FR2846008B1/en
Application filed by Centre National de la Recherche Scientifique CNRS, Universite Victor Segalen Bordeaux 2, Universite de Poitiers filed Critical Centre National de la Recherche Scientifique CNRS
Priority to FR0308289A priority Critical patent/FR2846009B1/en
Priority to AU2003285413A priority patent/AU2003285413A1/en
Priority to ES03778411T priority patent/ES2279975T3/en
Priority to US10/531,594 priority patent/US8129402B2/en
Priority to DE60310744T priority patent/DE60310744T2/en
Priority to CA2502544A priority patent/CA2502544C/en
Priority to EP03778411A priority patent/EP1551992B1/en
Priority to AT03778411T priority patent/ATE349550T1/en
Priority to PCT/FR2003/003101 priority patent/WO2004035813A2/en
Priority to JP2005501302A priority patent/JP4529030B2/en
Publication of FR2846009A1 publication Critical patent/FR2846009A1/en
Priority to US11/483,822 priority patent/US20070031821A1/en
Publication of FR2846009B1 publication Critical patent/FR2846009B1/en
Application granted granted Critical
Priority to US12/858,235 priority patent/US20110092483A1/en
Priority to US13/328,611 priority patent/US20120122916A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

A kit used to screen agents for antiprion activity comprising a yeast (A) having the (PSI+) phenotype and an antibiogram, is new. Independent claims are also included for: (1) method of screening compounds for antiprion activity comprising culturing a lawn of (A) in vitro, applying test compounds by the antibiogram method, incubation for 2-4 days at 20-25 degreesC and analysis of the coloration of cell colonies; and (2) antiprion agents of formula (I). R' = hydrogen, amino or NHR2; R2 = 1-10C alkyl or alkylaminoalkyl; X = fluoro, chloro, bromo, iodo, trifluoromethyl, methylthio, methoxy, hydroxy, nitro, acetyl, aminocarbonyl, carboxy or COOR3; R3 = 1-4C alkyl; p and n = 0-2; and q = 0 or 1.
FR0308289A 2002-10-18 2003-07-07 SCREENING OF MOLECULES WITH ANTI-PRION ACTIVITY: KITS, METHODS AND CRIBLE MOLECULES Expired - Fee Related FR2846009B1 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
FR0308289A FR2846009B1 (en) 2002-10-18 2003-07-07 SCREENING OF MOLECULES WITH ANTI-PRION ACTIVITY: KITS, METHODS AND CRIBLE MOLECULES
AT03778411T ATE349550T1 (en) 2002-10-18 2003-10-20 SERIES TESTING FOR MOLECULES WITH ANTI-PRION ACTIVITY: KITS, METHODS AND MOLECULES
JP2005501302A JP4529030B2 (en) 2002-10-18 2003-10-20 Screening kit for molecules having anti-prion activity, screening method for molecules having anti-prion activity, and screened molecules
ES03778411T ES2279975T3 (en) 2002-10-18 2003-10-20 SCREENING OF MOLECULES WITH ANTIPRIONIC ACTIVITY: KITS, METHODS AND MOLECULES CRIBATED
US10/531,594 US8129402B2 (en) 2002-10-18 2003-10-20 Screening molecules with anti-prion activity: kits, methods and screened molecules
DE60310744T DE60310744T2 (en) 2002-10-18 2003-10-20 SERIES TEST PROCEDURE FOR MOLECULES WITH ANTI-PRION ACTIVITY: KITS, METHODS AND MOLECULES
CA2502544A CA2502544C (en) 2002-10-18 2003-10-20 Screening molecules with anti-prion activity: kits, methods and screened molecules
EP03778411A EP1551992B1 (en) 2002-10-18 2003-10-20 Screening molecules with anti-prion activity: kits, methods and screened molecules
AU2003285413A AU2003285413A1 (en) 2002-10-18 2003-10-20 Screening molecules with anti-prion activity: kits, methods and screened molecules
PCT/FR2003/003101 WO2004035813A2 (en) 2002-10-18 2003-10-20 Screening molecules with anti-prion activity: kits, methods and screened molecules
US11/483,822 US20070031821A1 (en) 2002-10-18 2006-07-11 Screening molecules with anti-prion activity: kits, methods and screened molecules
US12/858,235 US20110092483A1 (en) 2002-10-18 2010-08-17 Screening molecules with anti-prion activity: kits, methods and screened molecules
US13/328,611 US20120122916A1 (en) 2002-10-18 2011-12-16 Screening molecules with anti-prion activity: kits, methods and screened molecules

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0213022A FR2846008B1 (en) 2002-10-18 2002-10-18 SCREENING OF MOLECULES WITH ANTI-PRION ACTIVITY: KITS, METHODS AND CRIBLE MOLECULES
FR0308289A FR2846009B1 (en) 2002-10-18 2003-07-07 SCREENING OF MOLECULES WITH ANTI-PRION ACTIVITY: KITS, METHODS AND CRIBLE MOLECULES

Publications (2)

Publication Number Publication Date
FR2846009A1 FR2846009A1 (en) 2004-04-23
FR2846009B1 true FR2846009B1 (en) 2007-10-12

Family

ID=32071174

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0308289A Expired - Fee Related FR2846009B1 (en) 2002-10-18 2003-07-07 SCREENING OF MOLECULES WITH ANTI-PRION ACTIVITY: KITS, METHODS AND CRIBLE MOLECULES

Country Status (10)

Country Link
US (4) US8129402B2 (en)
EP (1) EP1551992B1 (en)
JP (1) JP4529030B2 (en)
AT (1) ATE349550T1 (en)
AU (1) AU2003285413A1 (en)
CA (1) CA2502544C (en)
DE (1) DE60310744T2 (en)
ES (1) ES2279975T3 (en)
FR (1) FR2846009B1 (en)
WO (1) WO2004035813A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1908465B1 (en) * 2006-10-04 2009-04-29 Centre National De La Recherche Scientifique (Cnrs) Use of chlorine guanabenz derivatives for treating prion-based diseases
CN101481729B (en) * 2009-01-21 2014-04-16 辽宁大学 High-sensitivity method for screening anti-prion medicament by using gene mutation yeast cell
WO2018073321A1 (en) 2016-10-18 2018-04-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) Natural product derivatives for inhibiting cellular necroptosis, ferroptosis and oxytosis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3758479A (en) * 1967-03-22 1973-09-11 Sandoz Ag Nitro and sulphamoyl substituted dibenzodiazepines
DE2430380C3 (en) * 1974-06-25 1980-04-30 Behringwerke Ag, 3550 Marburg Manufacture of a substance with an immunological effect
JPH0262826A (en) * 1988-08-30 1990-03-02 Sawai Seiyaku Kk Remedy for adult t-cell leukemia
EP0565491A1 (en) * 1992-04-10 1993-10-13 Dornag Ag Coupling device, specially for coupling a toolholder to a driving spindle
US5472714A (en) * 1993-09-08 1995-12-05 Ciba-Geigy Corporation Double-layered oxcarbazepine tablets
US7799535B1 (en) * 1997-12-09 2010-09-21 Arch Development Corporation Methods for identifying factors that control the folding of amyloid proteins of diverse origin
CN1189175C (en) * 1998-10-08 2005-02-16 高新研究公司 Novel compsns. and methods for prevention and treatment of protozoal disease
US6200771B1 (en) * 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
EP1377554A1 (en) 1999-06-16 2004-01-07 University Of Iowa Research Foundation Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases
EP1392849B2 (en) * 2001-02-15 2012-01-18 University Of Chicago Yeast screens for agents affecting protein folding

Also Published As

Publication number Publication date
US20110092483A1 (en) 2011-04-21
US20120122916A1 (en) 2012-05-17
CA2502544A1 (en) 2004-04-29
EP1551992B1 (en) 2006-12-27
WO2004035813A3 (en) 2004-07-15
FR2846009A1 (en) 2004-04-23
JP4529030B2 (en) 2010-08-25
JP2006502745A (en) 2006-01-26
ES2279975T3 (en) 2007-09-01
AU2003285413A1 (en) 2004-05-04
US8129402B2 (en) 2012-03-06
WO2004035813A2 (en) 2004-04-29
DE60310744D1 (en) 2007-02-08
AU2003285413A8 (en) 2004-05-04
EP1551992A2 (en) 2005-07-13
US20060172337A1 (en) 2006-08-03
ATE349550T1 (en) 2007-01-15
CA2502544C (en) 2012-11-20
DE60310744T2 (en) 2007-10-11
US20070031821A1 (en) 2007-02-08

Similar Documents

Publication Publication Date Title
Conconi et al. Effects of hyperbaric oxygen on proliferative and apoptotic activities and reactive oxygen species generation in mouse fibroblast 3T3/J2 cell line
DK1242822T3 (en) Methods for detecting amyloidogenic proteins
CY1108630T1 (en) EXAMINATION OF BIOSOBILITY FOR COMPOSITIONS CONTAINING IRON
NO20062118L (en) Inhibitor contrast agents
DK0741694T3 (en) Phenylacetic acid derivatives, processes and intermediates for their preparation and agents containing them
NO20022095L (en) Heterocyclic substituted pyrazolones
DK1910381T3 (en) Substituted 1-oxa-3,8-diazaspiro [4,5] -decane-2-one compounds and their use in the manufacture of drugs
NO20071116L (en) Radicals and their use as paramagnetic agents in a DNP process
CY1109807T1 (en) DETERMINATION OF DIAMINE OXIDE
AU2003274412A1 (en) Kit and process for microbiological for on-site examination of a liquid sample
NO20072005L (en) New heterocyclic amides
FR2846009B1 (en) SCREENING OF MOLECULES WITH ANTI-PRION ACTIVITY: KITS, METHODS AND CRIBLE MOLECULES
IL166539A (en) Method for diagnosing multiple sclerosis
WO2002066975A3 (en) Tissue-based water quality biosensors for detecting chemical warfare agents
DK0914605T3 (en) Molecule model for VLA-4 inhibitors
NO20072431L (en) Process and Intermediates for Preparation of N- (1-Benzohydryl-azetidin-3-yl -) - N-phenylmethylsulfonamide Derivatives
AU2003230916A1 (en) Ex vivo method for determination of cetp activity and efficacy of heart disease treatment
FR2894594B1 (en) PREDICTIVE TEST FOR THERAPEUTIC RESPONSE TO BREAST CANCER
EP1801231A4 (en) SCREENING METHOD FOR A BAFF SUPPRESSOR OR INHIBITOR
WO2010006616A3 (en) Method and kit for examination of cells using n-(9-acridinyl)maleimide (nam) or using 7-diethylamino-3-((4'-(iodoacetyl)amino)phenyl)-4-methylcoumarin (cpi)
小林平造 et al. Z4 Repository
MX2008013437A (en) Method for administering tolperisone.
DE60126776D1 (en) METHOD FOR SELECTIVELY SURVIVAL OR GROWTH OF TARGET CELLS BY USING A CONJUGATE AND THEIR USE IN THERAPY AND DIAGNOSIS
ES2188320B1 (en) IMMUNOENZYMATIC METHOD (ELISA) TO QUANTIFY THE DEFICIENCY OF IRON IN FITOPLANCTON USING PHOTOSYNTHETIC PROTEINS.
UA51426A (en) Method for diagnosing non-susceptibility to infections

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20160331